William Ringo

Mr. Ringo became a director in July 2014, upon the closing of the Assembly Pharmaceuticals acquisition, and was named non-executive Chairman in 2015. From 2010 until 2015, Mr. Ringo served as a Senior Advisor at Barclays Capital, the global investment banking division of Barclays Bank PLC, and also as Strategic Advisor at Sofinnova Ventures, a life sciences-focused investment firm. Previously, Mr. Ringo served as Senior Vice President of Strategy and Business Development for Pfizer. Prior to joining Pfizer, Mr. Ringo was President and Chief Executive Officer of Abgenix, a public biotechnology company later acquired by Amgen. His experience in the global pharmaceutical sector also includes nearly 30 years with Eli Lilly and Co., where, he held a number of executive roles and was a member of Lilly’s operating committee. Mr. Ringo currently serves as a director for Sangamo Therapeutics, Inc., Immune Design Corp., Dermira and Five Prime Therapeutics. He previously served as a director of Onyx Pharmaceuticals until it was acquired by Amgen, Encysive Pharmaceuticals, Inspire Pharmaceuticals, Mirati Therapeutics and InterMune, where he became Executive Chairman after serving as interim Chief Executive Officer. Mr. Ringo also was director and Chairman of Community Health Systems. Mr. Ringo received a BS in Business Administration and an MBA from the University of Dayton.
Independent Director